Drug Database
IN

infliximab (infliximab, Epirus / BOW015 / Infimab)

✓ Approved

Ranbaxy Laboratories Limited · TNF · 单克隆抗体

什么是 infliximab?

infliximab 是一种单克隆抗体,由Ranbaxy Laboratories Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intraocular Injection、Intravenous (IV)。

药物档案

商品名infliximab, Epirus, BOW015, Infimab
公司Ranbaxy Laboratories Limited
药物类别单克隆抗体, 抗体
分子靶点TNF
给药途径Injectable (Others), Intraocular Injection, Intravenous (IV)
状态Approved

作用机制

分子靶点

infliximab 作用于 1 个分子靶点:

TNFtumor necrosis factor (TNFA, TNF-alpha)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

infliximab 针对 7 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersAnal fistula✓ Approved
Musculoskeletal and connective tissue disordersAnkylosing spondylitis✓ Approved
Gastrointestinal disordersColitis ulcerative✓ Approved
Gastrointestinal disordersCrohn's disease✓ Approved
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

注册免费账户还可查看另外 2 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedJournal of pediatric gastroenterology and nutrition2026-11-17

Baseline TNF-α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease.

Kwon Yiyoung Y, Kim Eun Sil ES, Kim Yoon Zi YZ, Jeong Tae Jong TJ et al.

Crohn's disease (CD) is a systemic disorder in which conventional luminal endoscopic assessments may incompletely reflect overall inflammatory burden. We aimed to evaluate the associations between baseline inflammatory cytokines, disease phenotype, infliximab (IFX) pharmacokinetics, and the need for dose intensification (DI) in pediatric CD. This prospective study included pediatric patients with moderate-to-severe CD treated with IFX. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) levels were measured at diagnosis. Baseline imbalances were adjusted using propensity score matching and inverse probability of treatment weighting analyses. Of the 160 enrolled patients, 15 (9.4%) were not included in the 1-year analysis, and 145 (90.6%) completed the 1-year follow-up. Body mass index (BMI)-adjusted TNF-α levels correlated with erythrocyte sedimentation rate (R = 0.22, p = 0.008) and fecal calprotectin (R = 0.34, p < 0.001), but not with simple endoscopic score for CD. In contrast, IL-6 levels were not significantly associated with inflammatory biomarkers. Cytokine profiles and IFX trough levels were not associated with perianal disease status or disease location. DI was required in 94 of 145 patients (64.8%), and patients requiring DI demonstrated higher baseline TNF-α levels than those without DI (49.63 ± 29.09 vs. 40.14 ± 16.59 pg/mL, p = 0.046). Higher baseline TNF-α levels were associated with subsequent IFX DI, while also correlating with conventional inflammatory biomarkers but not with SES-CD or anatomical disease phenotype. These findings suggest that baseline TNF-α may reflect an aspect of inflammatory burden relevant to subsequent treatment requirements that is not captured by luminal endoscopic severity or anatomical disease classification alone.

PMID 43042664
阅读全文 →
PubMedFrontiers in immunology2026-11-17

Immune-epithelial coordination of barrier repair in inflammatory bowel disease: from cell survival to functional healing.

Wu Ben B, He Bin-Sheng BS

Epithelial repair in inflammatory bowel disease involves preservation of viable cells, coverage of wounds, renewal of epithelial populations and recovery of selective transport and secretion. These processes overlap, yet improvement in one does not establish completion of the others. This narrative review examines how immune signals influence these transitions and how experimental repair findings relate to patient outcomes. We first describe the junctional and mucus barrier and the distinction between physiological, endoscopic and histological measurements. We then examine epithelial death control, regenerative pathways and immune-derived signals using studies selected for compartment-specific perturbation, functional measurements or informative discrepancies between experimental and clinical findings. Interleukin-22 illustrates the importance of context: it promotes regeneration in several experimental systems, disrupts barrier function in a human colon chip, and has not yielded demonstrated efficacy as efmarodocokin alfa in a phase II ulcerative colitis trial. In one small infliximab study, paired measurements from nine patients showed an increase in epithelial resistance after treatment. Larger controlled studies are needed to establish how consistently functional recovery accompanies immune control. We organize the evidence around target engagement, epithelial response, barrier function and patient benefit, with example assays and common interpretive pitfalls for each. The resulting synthesis identifies the measurements needed to distinguish protection from repair and to test whether an epithelial effect adds value to effective immune therapy. Clinical studies must ultimately establish that a specified functional improvement is durable and beneficial to patients.

PMID 43041937
阅读全文 →
PubMedJournal of translational autoimmunity2026-11-15

Impact of infliximab combined with methotrexate on serum inflammatory and immunometabolic biomarkers in rheumatoid arthritis.

Al-Maslamani Bilal B, Soudi Sara S, Al-Ghazaly Zakariya Muayad ZM

Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with metabolic reprogramming of immune cells. Although inflammatory cytokines have been extensively studied, the effects of disease-modifying therapies including methotrexate, infliximab and their combination on serum immunometabolic biomarkers remain incompletely understood. This cross-sectional study included newly diagnosed RA patients, patients receiving MTX monotherapy, patients receiving MTX plus infliximab, and healthy controls. Serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), lactate, citrate, and succinate dehydrogenase (SDH) activity were measured. Disease activity was evaluated using the Disease Activity Score in 28 joints (DAS28). Statistical analyses, hierarchical clustering, correlation and network analyses, principal component analysis (PCA), and exploratory structural equation modeling (SEM) were used to investigate immunometabolic relationships and treatment-associated changes. Newly diagnosed RA patients showed significantly elevated TNF-α, IL-10, lactate, SDH activity, TNF-α/IL-10 ratio, and DAS28, alongside reduced citrate levels compared with controls and treated patients. Combined MTX and infliximab therapy demonstrated the greatest improvement in inflammatory and metabolic biomarkers and the lowest disease activity. Multivariate analyses identified TNF-α, lactate, and DAS28 as major contributors to disease-associated variation, while citrate displayed an opposing metabolic pattern. Correlation and network analyses identified TNF-α as a central link between inflammation, metabolic remodeling, and disease severity. SEM suggested that treatment-associated reductions in TNF-α were related to decreased glycolytic activity, improved mitochondrial metabolism, and reduced disease activity. RA involves coordinated inflammatory and metabolic dysregulation. Combined MTX and infliximab therapy appears more effective than MTX alone in restoring immunometabolic balance.

PMID 43032676
阅读全文 →
PubMedACG case reports journal2026-11-15

Advanced Combination Therapy for Pediatric Isolated Upper Gastrointestinal Crohn's Disease.

Towbin Noah N, Huebner Thomas T, Arai Ronen R

Isolated upper gastrointestinal (UGI) Crohn's disease (CD) is uncommon and frequently presents nonspecifically, leading to diagnostic delay. We present, a 15-year-old adolescent boy with family history of ileal CD presented with nausea, vomiting, weight loss, and alternating diarrhea and constipation. Endoscopy with histology demonstrated isolated UGI CD. Advanced combination therapy with infliximab and upadacitinib was initiated. The patient's symptoms resolved and endoscopic mucosal improvement and histologic normalization occurred within four months. Following a taper of upadacitinib and continued infliximab, the patient remains in remission. This case supports use of advanced combination therapy for UGI CD.

PMID 43032779
阅读全文 →
PubMedEuropean radiology2026-11-15

A nomogram integrating clinical and radiological data to predict long-term infliximab efficacy in Crohn's disease.

Shi Xuan X, Chen Xiaoshan X, Rao Shengxiang S, Liu Taotao T et al.

Infliximab (IFX) is a monoclonal antibody to treat Crohn's disease (CD), but loss of response is common. We aimed to develop an effective nomogram to predict long-term outcomes of IFX. A retrospective observational study was conducted on CD patients receiving regular IFX. The endpoint was defined as loss of response within 78 weeks, further classified as uncomplicated or complicated. Baseline characteristics, pre- and postinduction clinical indicators, and computed tomography enterography imaging features were collected. Candidate predictors were selected using the least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic regression to construct a clinical-radiological nomogram, validated using receiver operating characteristic (ROC) analysis, decision curve analysis, and calibration plots. Kaplan-Meier analysis evaluated the clinical implications of predictor cut-off values. The study enrolled 165 patients, with 112 in the training cohort and 53 in the validation cohort. LASSO-logistic regression revealed erythrocyte sedimentation rate (ESR) at week 14 and maximum small bowel wall thickness (SBWT-max) at baseline as independent predictors of long-term non-response. The nomogram achieved an area under the curve (AUC) of 0.834 (training) and 0.913 (validation) for loss of response, and 0.746 and 0.876 for uncomplicated and complicated loss of response, respectively. Validation of the nomogram confirmed its discriminative, calibrating, and clinical utility. Additionally, ESR at week 14 > 10.5 mm/h or baseline SBWT-max > 7.5 mm showed reduced response duration. The feasible nomogram combining ESR postinduction and SBWT-max at baseline effectively predicts long-term efficacy of IFX, which guides the therapy for CD patients. QuestionLoss of response to infliximab is common in Crohn's disease, yet a reliable tool to predict long-term efficacy and guide timely therapeutic decisions remains rare. FindingsA nomogram based on LASSO-logistic regression integrating postinduction ESR and baseline maximum small bowel wall thickness accurately predicted long-term loss of response, including complicated failure. Clinical relevanceThis validated nomogram enables early, risk-stratified identification of patients likely to develop uncomplicated versus complicated loss of response, guiding proactive therapy switch and personalized management in Crohn's disease.

PMID 43034256
阅读全文 →
PubMedZeitschrift fur Gastroenterologie2026-11-14

[Adjunctive enteral nutrition in Crohn's disease during biologic therapy: More than a supportive measure? A narrative review].

Peters Sarah S, Tessmer Lea L, Dignass Axel A, Stein Jürgen J

This narrative review aimed to critically evaluate evidence for combining enteral nutrition (EN) with biologic therapy in adults with Crohn's disease (CD). PubMed, Embase and the Cochrane Library were searched on EN combined with biologics, incl. infliximab, adalimumab, vedolizumab, and ustekinumab. Studies published from 01/2018-06/2026 and current clinical guidelines were considered. The evidence was evaluated regarding clinical effectiveness and methodological limitations. Current evidence suggests that adding enteral nutrition to biologic therapy may relatively increase clinical and endoscopic remission rates by up to 50 % compared with biologic monotherapy. The potential benefit may be due to enhanced mucosal healing, alterations in the intestinal microbiome, and improved pharmacokinetics. Higher rates of transmural healing and lower relapse, treatment escalation, and surgery rates have also been reported. While exclusive EN has a broader evidence base, partial EN may offer advantages in clinical practice because of its greater feasibility and acceptability. Evidence is limited by selection bias, heterogeneous treatment protocols and lack of blinding. Combining EN with biologics is a promising therapeutic approach for adults with CD. Prospective RCTs are needed to establish efficacy, safety and optimal use of exclusive and partial EN.

PMID 43025458
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多infliximab